

Contents

PART I AN INTRODUCTION TO IMMUNOBIOLOGY AND INNATE IMMUNITY

Chapter 1	Basic Concepts in Immunology	1
Chapter 2	Innate Immunity: The First Lines of Defense	37
Chapter 3	The Induced Responses of Innate Immunity	75

PART II THE RECOGNITION OF ANTIGEN

Chapter 4	Antigen Recognition by B-cell and T-cell Receptors	127
Chapter 5	The Generation of Lymphocyte Antigen Receptors	157
Chapter 6	Antigen Presentation to T Lymphocytes	201

PART III THE DEVELOPMENT OF MATURE LYMPHOCYTE RECEPTOR REPERTOIRES

Chapter 7	Signaling Through Immune-System Receptors	239
Chapter 8	The Development and Survival of Lymphocytes	275

PART IV THE ADAPTIVE IMMUNE RESPONSE

Chapter 9	T Cell-Mediated Immunity	335
Chapter 10	The Humoral Immune Response	387
Chapter 11	Dynamics of Adaptive Immunity	429
Chapter 12	The Mucosal Immune System	465

PART V THE IMMUNE SYSTEM IN HEALTH AND DISEASE

Chapter 13	Failures of Host Defense Mechanisms	509
Chapter 14	Allergy and Allergic Diseases	571
Chapter 15	Autoimmunity and Transplantation	611
Chapter 16	Manipulation of the Immune Response	669

Appendix I	Immunologist's Toolbox with Immunological Constants	717
Appendix II	CD Antigens	763
Appendix III	Cytokines and Their Receptors	779
Appendix IV	Chemokines and Their Receptors	782
Biographies		784
Glossary		786
Index		823

Detailed Contents

Part I

AN INTRODUCTION TO IMMUNO-BIOLOGY AND INNATE IMMUNITY

Chapter 1 Basic Concepts in Immunology 1

Principles of innate and adaptive immunity. 3

- 1-1 The immune system recognizes infection and induces protective responses. 3
- 1-2 The cells of the immune system derive from precursors in the bone marrow. 4
- 1-3 The myeloid lineage comprises most of the cells of the innate immune system. 4
- 1-4 The lymphoid lineage comprises the lymphocytes of the adaptive immune system and the natural killer cells of innate immunity. 8
- 1-5 Lymphocytes mature in the bone marrow or the thymus and then congregate in lymphoid tissues throughout the body. 9
- 1-6 Most infectious agents activate the innate immune system and induce an inflammatory response. 10
- 1-7 Pattern recognition receptors of the innate immune system provide an initial discrimination between self and nonself. 11
- 1-8 Adaptive immune responses are initiated by antigen and antigen-presenting cells in secondary lymphoid tissues. 12
- 1-9 Lymphocytes activated by antigen give rise to clones of antigen-specific effector cells that mediate adaptive immunity. 12
- 1-10 Clonal selection of lymphocytes is the central principle of adaptive immunity. 13
- 1-11 The structure of the antibody molecule illustrates the central puzzle of adaptive immunity. 14
- 1-12 Each developing lymphocyte generates a unique antigen receptor by rearranging its receptor gene segments. 15
- 1-13 Immunoglobulins bind a wide variety of chemical structures, whereas the T-cell receptor is specialized to recognize foreign antigens as peptide fragments bound to proteins of the major histocompatibility complex. 16
- 1-14 The development and survival of lymphocytes is determined by signals received through their antigen receptors. 17
- 1-15 Lymphocytes encounter and respond to antigen in the peripheral lymphoid organs. 17
- 1-16 Lymphocyte activation requires additional signals beyond those relayed from the antigen receptor when antigen binds. 21
- 1-17 Lymphocytes activated by antigen proliferate in the peripheral lymphoid organs, generating effector cells and immunological memory. 22

Summary. 25

The effector mechanisms of adaptive immunity. 25

- 1-18 Antibodies protect against extracellular pathogens and their toxic products. 26
- 1-19 T cells orchestrate cell-mediated immunity and regulate B-cell responses to most antigens. 28
- 1-20 CD4 and CD8 T cells recognize peptides bound to two different classes of MHC molecules. 29
- 1-21 Inherited and acquired defects in the immune system result in increased susceptibility to infection. 31

- 1-22 Understanding adaptive immune responses is important for the control of allergies, autoimmune disease, and the rejection of transplanted organs. 32

- 1-23 Vaccination is the most effective means of controlling infectious diseases. 33

Summary. 34

Summary to Chapter 1. 35

General references. 36

Chapter 2: Innate Immunity: The First Lines of Defense 37

The first lines of defense. 38

- 2-1 Infectious diseases are caused by diverse living agents that replicate in their hosts. 38
- 2-2 Infectious agents must overcome innate host defenses to establish a focus of infection. 42
- 2-3 Epithelial surfaces of the body provide the first line of defense against infection. 43
- 2-4 Epithelial cells and phagocytes produce several kinds of antimicrobial proteins. 44

Summary. 47

The complement system and innate immunity. 48

- 2-5 The complement system recognizes features of microbial surfaces and marks them for destruction by the deposition of C3b. 50
- 2-6 The lectin pathway uses soluble receptors that recognize microbial surfaces to activate the complement cascade. 52
- 2-7 The classical pathway is initiated by activation of the C1 complex and is homologous to the lectin pathway. 55
- 2-8 Complement activation is largely confined to the surface on which it is initiated. 56
- 2-9 The alternative pathway is an amplification loop for C3b formation that is accelerated by recognition of pathogens by properdin. 57
- 2-10 Membrane and plasma proteins that regulate the formation and stability of C3 convertases determine the extent of complement activation under different circumstances. 59
- 2-11 Complement developed early in the evolution of multicellular organisms. 61
- 2-12 Surface-bound C3 convertase deposits large numbers of C3b fragments on pathogen surfaces and generates C5 convertase activity. 62
- 2-13 Ingestion of complement-tagged pathogens by phagocytes is mediated by receptors for the bound complement proteins. 62
- 2-14 The small fragments of some complement proteins initiate a local inflammatory response. 64
- 2-15 The terminal complement proteins polymerize to form pores in membranes that can kill certain pathogens. 65
- 2-16 Complement control proteins regulate all three pathways of complement activation and protect the host from their destructive effects. 66

Summary. 71

Questions. 71

Section references. 72

Chapter 3 The Induced Responses of Innate Immunity 75

Pattern recognition by cells of the innate immune system. 75

- 3-1 After entering tissues, many pathogens are recognized, ingested, and killed by phagocytes. 76
- 3-2 G-protein-coupled receptors on phagocytes link microbe recognition with increased efficiency of intracellular killing. 78
- 3-3 Pathogen recognition and tissue damage initiate an inflammatory response. 82
- 3-4 Toll-like receptors represent an ancient pathogen-recognition system. 85
- 3-5 Mammalian Toll-like receptors are activated by many different pathogen-associated molecular patterns. 85
- 3-6 TLR-4 recognizes bacterial lipopolysaccharide in association with the host accessory proteins MD-2 and CD14. 88
- 3-7 TLRs activate the transcription factors NF κ B, AP-1, and IRF to induce the expression of inflammatory cytokines and type I interferons. 89
- 3-8 The NOD-like receptors act as intracellular sensors of bacterial infection. 92
- 3-9 The RIG-I-like helicases detect cytoplasmic viral RNAs and stimulate interferon production. 94
- 3-10 Activation of TLRs and NLRs triggers changes in gene expression in macrophages and dendritic cells that have far-reaching effects on the immune response. 96
- 3-11 TLR signaling shares many components with Toll signaling in *Drosophila*. 97
- 3-12 TLR and NOD genes have undergone extensive diversification in both invertebrates and some primitive chordates. 98
- Summary. 98

Induced innate responses to infection. 99

- 3-13 Macrophages and dendritic cells activated by pathogens secrete a range of cytokines that have a variety of local and distant effects. 99
- 3-14 Chemokines released by macrophages and dendritic cells recruit effector cells to sites of infection. 102
- 3-15 Cell-adhesion molecules control interactions between leukocytes and endothelial cells during an inflammatory response. 103
- 3-16 Neutrophils make up the first wave of cells that cross the blood vessel wall to enter an inflamed tissue. 105
- 3-17 TNF- α is an important cytokine that triggers local containment of infection but induces shock when released systemically. 107
- 3-18 Cytokines released by macrophages and dendritic cells activate the acute-phase response. 109
- 3-19 Interferons induced by viral infection make several contributions to host defense. 111
- 3-20 NK cells are activated by interferon and macrophage-derived cytokines to serve as an early defense against certain intracellular infections. 113
- 3-21 NK cells possess receptors for self molecules that prevent their activation by uninfected cells. 113
- 3-22 NK cells bear receptors that activate their effector function in response to ligands expressed on infected cells or tumor cells. 117
- 3-23 The NKG2D receptor activates a different signaling pathway from that of the other activating NK receptors. 117
- 3-24 Several lymphocyte subpopulations behave as innate-like lymphocytes. 118
- Summary. 120
- Summary to Chapter 3. 120

- Questions. 121
- General references. 122
- Section references. 122

Part II THE RECOGNITION OF ANTIGEN

Chapter 4 Antigen Recognition by B-cell and T-cell Receptors 127

The structure of a typical antibody molecule. 128

- 4-1 IgG antibodies consist of four polypeptide chains. 129
- 4-2 Immunoglobulin heavy and light chains are composed of constant and variable regions. 130
- 4-3 The antibody molecule can readily be cleaved into functionally distinct fragments. 130
- 4-4 The immunoglobulin molecule is flexible, especially at the hinge region. 131
- 4-5 The domains of an immunoglobulin molecule have similar structures. 132
- Summary. 133

The interaction of the antibody molecule with specific antigen. 134

- 4-6 Localized regions of hypervariable sequence form the antigen-binding site. 134
- 4-7 Antibodies bind antigens via contacts with amino acids in CDRs, but the details of binding depend upon the size and shape of the antigen. 135
- 4-8 Antibodies bind to conformational shapes on the surfaces of antigens. 136
- 4-9 Antigen-antibody interactions involve a variety of forces. 136
- Summary. 138

Antigen recognition by T cells. 138

- 4-10 The T-cell receptor is very similar to a Fab fragment of immunoglobulin. 139
- 4-11 A T-cell receptor recognizes antigen in the form of a complex of a foreign peptide bound to an MHC molecule. 140
- 4-12 There are two classes of MHC molecules with distinct subunit compositions but similar three-dimensional structures. 141
- 4-13 Peptides are stably bound to MHC molecules, and also serve to stabilize the MHC molecule on the cell surface. 142
- 4-14 MHC class I molecules bind short peptides of 8–10 amino acids by both ends. 143
- 4-15 The length of the peptides bound by MHC class II molecules is not constrained. 145
- 4-16 The crystal structures of several peptide:MHC:T-cell receptor complexes show a similar orientation of the T-cell receptor over the peptide:MHC complex. 147
- 4-17 The CD4 and CD8 cell-surface proteins of T cells are required to make an effective response to antigen. 148
- 4-18 The two classes of MHC molecules are expressed differentially on cells. 150
- 4-19 A distinct subset of T cells bears an alternative receptor made up of γ and δ chains. 151
- Summary. 152
- Summary to Chapter 4. 152
- Questions. 153
- General references. 154
- Section references. 154

Chapter 5	The Generation of Lymphocyte Antigen Receptors	157		
	Primary immunoglobulin gene rearrangement.	158		
5-1	Immunoglobulin genes are rearranged in antibody-producing cells.	158	5-22	RAG-dependent adaptive immunity based on a diversified repertoire of immunoglobulin-like genes appeared abruptly in the cartilaginous fishes.
5-2	Complete genes that encode a variable region are generated by the somatic recombination of separate gene segments.	159	5-23	Different species generate immunoglobulin diversity in different ways.
5-3	Multiple contiguous V gene segments are present at each immunoglobulin locus.	160	5-24	Both $\alpha:\beta$ and $\gamma:\delta$ T-cell receptors are present in cartilaginous fish.
5-4	Rearrangement of V, D, and J gene segments is guided by flanking DNA sequences.	161	5-25	MHC class I and class II molecules are also first found in the cartilaginous fishes.
5-5	The reaction that recombines V, D, and J gene segments involves both lymphocyte-specific and ubiquitous DNA-modifying enzymes.	162		Summary.
5-6	The diversity of the immunoglobulin repertoire is generated by four main processes.	166		Summary to Chapter 5.
5-7	The multiple inherited gene segments are used in different combinations.	166		Questions.
5-8	Variable addition and subtraction of nucleotides at the junctions between gene segments contributes to the diversity of the third hypervariable region.	167		General references.
	Summary.	168		Section references.
	T-cell receptor gene rearrangement.	169	Chapter 6	Antigen Presentation to T Lymphocytes
5-9	The T-cell receptor gene segments are arranged in a similar pattern to immunoglobulin gene segments and are rearranged by the same enzymes.	169		201
5-10	T-cell receptors concentrate diversity in the third hypervariable region.	171		The generation of T-cell receptor ligands.
5-11	$\gamma:\delta$ T-cell receptors are also generated by gene rearrangement.	172		202
	Summary.	173	6-1	The MHC class I and class II molecules deliver peptides to the cell surface from two intracellular compartments.
	Structural variation in immunoglobulin constant regions.	173	6-2	Peptides that bind to MHC class I molecules are actively transported from the cytosol to the endoplasmic reticulum.
5-12	Different classes of immunoglobulins are distinguished by the structure of their heavy-chain constant regions.	174	6-3	Peptides for transport into the endoplasmic reticulum are generated in the cytosol.
5-13	The constant region confers functional specialization on the antibody.	175	6-4	Newly synthesized MHC class I molecules are retained in the endoplasmic reticulum until they bind a peptide.
5-14	Mature naive B cells express both IgM and IgD at their surface.	176	6-5	Many viruses produce immunoevasins that interfere with antigen presentation by MHC class I molecules.
5-15	Transmembrane and secreted forms of immunoglobulin are generated from alternative heavy-chain transcripts.	177	6-6	Peptides presented by MHC class II molecules are generated in acidified endocytic vesicles.
5-16	IgM and IgA can form polymers.	178	6-7	The invariant chain directs newly synthesized MHC class II molecules to acidified intracellular vesicles.
	Summary.	179	6-8	A specialized MHC class II-like molecule catalyzes loading of MHC class II molecules with peptides.
	Secondary diversification of the antibody repertoire.	179	6-9	Cross-presentation allows exogenous proteins to be presented on MHC class I molecules by a restricted set of antigen-presenting cells.
5-17	Activation-induced cytidine deaminase (AID) introduces mutations into genes transcribed in B cells.	180	6-10	Stable binding of peptides by MHC molecules provides effective antigen presentation at the cell surface.
5-18	Somatic hypermutation further diversifies the rearranged V regions of immunoglobulin genes.	182		Summary.
5-19	Class switching enables the same assembled V_H exon to be associated with different C_H genes in the course of an immune response.	184		The major histocompatibility complex and its function.
	Summary.	186		217
	Evolution of the adaptive immune response.	186	6-11	Many proteins involved in antigen processing and presentation are encoded by genes within the MHC.
5-20	Some invertebrates generate extensive diversity in a repertoire of immunoglobulin-like genes.	187	6-12	The protein products of MHC class I and class II genes are highly polymorphic.
5-21	Agnathans possess an adaptive immune system that uses somatic gene rearrangement to diversify receptors built from LRR domains.	189	6-13	MHC polymorphism affects antigen recognition by T cells by influencing both peptide binding and the contacts between T-cell receptor and MHC molecule.
			6-14	Alloreactive T cells recognizing nonself MHC molecules are very abundant.
			6-15	Many T cells respond to superantigens.
			6-16	MHC polymorphism extends the range of antigens to which the immune system can respond.
			6-17	A variety of genes with specialized functions in immunity are also encoded in the MHC.
			6-18	Specialized MHC class I molecules act as ligands for the activation and inhibition of NK cells.
			6-19	The CD1 family of MHC class I-like molecules is encoded outside the MHC and presents microbial lipids to CD1-restricted T cells.

Summary.	233
Summary to Chapter 6.	233
Questions.	234
General references.	235
Section references.	235

Part III THE DEVELOPMENT OF MATURE LYMPHOCYTE RECEPTOR REPERTOIRES

Chapter 7 Signaling Through Immune-System Receptors 239

General principles of signal transduction and propagation. 239

7-1 Transmembrane receptors convert extracellular signals into intracellular biochemical events.	240
7-2 Intracellular signal propagation is mediated by large multiprotein signaling complexes.	242
7-3 Small G proteins act as molecular switches in many different signaling pathways.	243
7-4 Signaling proteins are recruited to the membrane by a variety of mechanisms.	244
7-5 Ubiquitin conjugation of proteins can both activate and inhibit signaling responses.	245
7-6 The activation of some receptors generates small-molecule second messengers.	246

Summary.	247
----------	-----

Antigen receptor signaling and lymphocyte activation. 247

7-7 Antigen receptors consist of variable antigen-binding chains associated with invariant chains that carry out the signaling function of the receptor.	247
7-8 Antigen recognition by the T-cell receptor and its co-receptors leads to phosphorylation of ITAMs by Src-family kinases.	249
7-9 Phosphorylated ITAMs recruit and activate the tyrosine kinase ZAP-70, which phosphorylates scaffold proteins that recruit the phospholipase PLC- γ .	251
7-10 The activation of PLC- γ requires a co-stimulatory signal.	251
7-11 Activated PLC- γ generates the second messengers diacylglycerol and inositol trisphosphate.	252
7-12 Ca^{2+} entry activates the transcription factor NFAT.	253
7-13 Ras activation stimulates the mitogen-activated protein kinase (MAPK) relay and induces expression of the transcription factor AP-1.	253
7-14 Protein kinase C activates the transcription factors NF κ B and AP-1.	256
7-15 The cell-surface protein CD28 is a co-stimulatory receptor for naive T cells.	257
7-16 The logic of B-cell receptor signaling is similar to that of T-cell receptor signaling, but some of the signaling components are specific to B cells.	258
7-17 ITAMs are also found in other receptors on leukocytes that signal for cell activation.	260
7-18 Inhibitory receptors on lymphocytes help regulate immune responses.	260

Summary.	263
----------	-----

Other receptors and signaling pathways. 264

7-19 Cytokines and their receptors fall into distinct families of structurally related proteins.	264
--------------------------------------------------------------------------------------------------	-----

7-20 Cytokine receptors of the hematopoietin family are associated with the JAK family of tyrosine kinases, which activate STAT transcription factors.	266
7-21 Cytokine signaling is terminated by a negative feedback mechanism.	267
7-22 The receptors that induce apoptosis activate specialized intracellular proteases called caspases.	267
7-23 The intrinsic pathway of apoptosis is mediated by the release of cytochrome <i>c</i> from mitochondria.	270

Summary.	270
----------	-----

Summary to Chapter 7.	271
-----------------------	-----

Questions.	272
------------	-----

General references.	272
---------------------	-----

Section references.	272
---------------------	-----

Chapter 8 The Development and Survival of Lymphocytes 275

Development of B lymphocytes. 276

8-1 Lymphocytes derive from hematopoietic stem cells in the bone marrow.	276
8-2 B-cell development begins by rearrangement of the heavy-chain locus.	278
8-3 The pre-B-cell receptor tests for successful production of a complete heavy chain and signals for the transition from the pro-B cell to pre-B cell stage.	282
8-4 Pre-B-cell receptor signaling inhibits further heavy-chain locus rearrangement and enforces allelic exclusion.	283
8-5 Pre-B cells rearrange the light-chain locus and express cell-surface immunoglobulin.	284
8-6 Immature B cells are tested for autoreactivity before they leave the bone marrow.	285

Summary.	290
----------	-----

The development of T lymphocytes in the thymus. 290

8-7 T-cell progenitors originate in the bone marrow, but all the important events in their development occur in the thymus.	291
8-8 T-cell precursors proliferate extensively in the thymus, but most die there.	294
8-9 Successive stages in the development of thymocytes are marked by changes in cell-surface molecules.	294
8-10 Thymocytes at different developmental stages are found in distinct parts of the thymus.	297
8-11 T cells with $\alpha:\beta$ or $\gamma:\delta$ receptors arise from a common progenitor.	298
8-12 T cells expressing particular γ - and δ -chain V regions arise in an ordered sequence early in life.	299
8-13 Successful synthesis of a rearranged β chain allows the production of a pre-T-cell receptor that triggers cell proliferation and blocks further β -chain gene rearrangement.	301
8-14 T-cell α -chain genes undergo successive rearrangements until positive selection or cell death intervenes.	304

Summary.	305
----------	-----

Positive and negative selection of T cells. 305

8-15 The MHC type of the thymic stroma selects a repertoire of mature T cells that can recognize foreign antigens presented by the same MHC type.	306
8-16 Only thymocytes whose receptors interact with self-peptide: self-MHC complexes can survive and mature.	307

8-17	Positive selection acts on a repertoire of T-cell receptors with inherent specificity for MHC molecules.	308
8-18	Positive selection coordinates the expression of CD4 or CD8 with the specificity of the T-cell receptor and the potential effector functions of the T cell.	308
8-19	Thymic cortical epithelial cells mediate positive selection of developing thymocytes.	310
8-20	T cells that react strongly with ubiquitous self antigens are deleted in the thymus.	311
8-21	Negative selection is driven most efficiently by bone marrow derived antigen-presenting cells.	313
8-22	The specificity and/or the strength of signals for negative and positive selection must differ.	314
	Summary.	315

Survival and maturation of lymphocytes in peripheral lymphoid tissues. 316

8-23	Different lymphocyte subsets are found in particular locations in peripheral lymphoid tissues.	316
8-24	The development of peripheral lymphoid tissues is controlled by lymphoid tissue inducer cells and proteins of the tumor necrosis factor family.	317
8-25	The homing of lymphocytes to specific regions of peripheral lymphoid tissues is mediated by chemokines.	319
8-26	Lymphocytes that encounter sufficient quantities of self antigens for the first time in the periphery are eliminated or inactivated.	320
8-27	Immature B cells arriving in the spleen turn over rapidly and require cytokines and positive signals through the B-cell receptor for maturation and survival.	321
8-28	B-1 cells and marginal zone B cells are distinct B-cell subtypes with unique antigen receptor specificity.	322
8-29	T-cell homeostasis in the periphery is regulated by cytokines and self-MHC interactions.	324
	Summary.	325
	Summary to Chapter 8.	325
	Questions.	329
	General references.	329
	Section references.	329

Part IV THE ADAPTIVE IMMUNE RESPONSE

Chapter 9 T Cell-Mediated Immunity 335

Entry of naive T cells and antigen-presenting cells into peripheral lymphoid organs. 337

9-1	Naive T cells migrate through peripheral lymphoid tissues, sampling the peptide:MHC complexes on dendritic cell surfaces.	337
9-2	Lymphocyte entry into lymphoid tissues depends on chemokines and adhesion molecules.	338
9-3	Activation of integrins by chemokines is responsible for the entry of naive T cells into lymph nodes.	339
9-4	T-cell responses are initiated in peripheral lymphoid organs by activated dendritic cells.	342
9-5	Dendritic cells process antigens from a wide array of pathogens.	344
9-6	Pathogen-induced TLR signaling in immature dendritic cells induces their migration to lymphoid organs and enhances antigen processing.	347

9-7	Plasmacytoid dendritic cells produce abundant type I interferons and may act as helper cells for antigen presentation by conventional dendritic cells.	349
9-8	Macrophages are scavenger cells that can be induced by pathogens to present foreign antigens to naive T cells.	350
9-9	B cells are highly efficient at presenting antigens that bind to their surface immunoglobulin.	351
	Summary.	352

Priming of naive T cells by pathogen-activated dendritic cells. 353

9-10	Cell-adhesion molecules mediate the initial interaction of naive T cells with antigen-presenting cells.	353
9-11	Antigen-presenting cells deliver three kinds of signals for the clonal expansion and differentiation of naive T cells.	354
9-12	CD28-dependent co-stimulation of activated T cells induces expression of the T-cell growth factor interleukin-2 and the high-affinity IL-2 receptor.	355
9-13	Signal 2 can be modified by additional co-stimulatory pathways.	356
9-14	Antigen recognition in the absence of co-stimulation leads to functional inactivation or clonal deletion of peripheral T cells.	357
9-15	Proliferating T cells differentiate into effector T cells that do not require co-stimulation to act.	358
9-16	CD8 T cells can be activated in different ways to become cytotoxic effector cells.	359
9-17	CD4 T cells differentiate into several subsets of functionally different effector cells.	360
9-18	Various forms of signal 3 induce the differentiation of naive CD4 T cells down distinct effector pathways.	362
9-19	Regulatory CD4 T cells are involved in controlling adaptive immune responses.	364
	Summary.	365

General properties of effector T cells and their cytokines. 366

9-20	Effector T-cell interactions with target cells are initiated by antigen-nonspecific cell-adhesion molecules.	366
9-21	An immunological synapse forms between effector T cells and their targets to regulate signaling and to direct the release of effector molecules.	367
9-22	The effector functions of T cells are determined by the array of effector molecules that they produce.	369
9-23	Cytokines can act locally or at a distance.	370
9-24	T cells express several TNF-family cytokines as trimeric proteins that are usually associated with the cell surface.	371
	Summary.	372

T cell-mediated cytotoxicity. 372

9-25	Cytotoxic T cells can induce target cells to undergo programmed cell death.	373
9-26	Cytotoxic effector proteins that trigger apoptosis are contained in the granules of CD8 cytotoxic T cells.	374
9-27	Cytotoxic T cells are selective and serial killers of targets expressing a specific antigen.	376
9-28	Cytotoxic T cells also act by releasing cytokines.	377
	Summary.	377

Macrophage activation by T_H1 cells. 377

9-29	T _H 1 cells have a central role in macrophage activation.	378
9-30	Activation of macrophages by T _H 1 cells promotes microbial killing and must be tightly regulated to avoid tissue damage.	378

9-21	T _H 1 cells coordinate the host response to intracellular pathogens.	379
Summary		380
Summary to Chapter 9.		381
Questions.		382
General references.		382
Section references.		382

Chapter 10 The Humoral Immune Response 387

B-cell activation by helper T cells. 388

10-1	The humoral immune response is initiated when B cells that bind antigen are signaled by helper T cells or by certain microbial antigens alone.	389
10-2	B-cell responses are enhanced by co-ligation of the B-cell receptor and B-cell co-receptor by antigen and complement fragments on microbial surfaces.	389
10-3	Helper T cells activate B cells that recognize the same antigen.	390
10-4	T cells make membrane-bound and secreted molecules that activate B cells.	391
10-5	B cells that encounter their antigens migrate toward the boundaries between B-cell and T-cell areas in secondary lymphoid tissues.	392
10-6	Antibody-secreting plasma cells differentiate from activated B cells.	395
10-7	The second phase of a primary B-cell immune response occurs when activated B cells migrate into follicles and proliferate to form germinal centers.	396
10-8	Germinal center B cells undergo V-region somatic hypermutation, and cells with mutations that improve affinity for antigen are selected.	398
10-9	Class switching in thymus-dependent antibody responses requires expression of CD40 ligand by helper T cells and is directed by cytokines.	400
10-10	Ligation of CD40 and prolonged contact with T follicular helper cells is required to sustain germinal center B cells.	402
10-11	Surviving germinal center B cells differentiate into either plasma cells or memory cells.	402
10-12	Some bacterial antigens do not require T-cell help to induce B-cell responses.	404
10-13	B-cell responses to bacterial polysaccharides do not require peptide-specific T-cell help.	405
Summary		407

The distributions and functions of immunoglobulin classes. 408

10-14	Antibodies of different classes operate in distinct places and have distinct effector functions.	408
10-15	Transport proteins that bind to the Fc regions of antibodies carry particular isotypes across epithelial barriers.	409
10-16	High-affinity IgG and IgA antibodies can neutralize bacterial toxins.	412
10-17	High-affinity IgG and IgA antibodies can inhibit the infectivity of viruses.	413
10-18	Antibodies can block the adherence of bacteria to host cells.	413
10-19	Antibody:antigen complexes activate the classical pathway of complement by binding to C1q.	414
10-20	Complement receptors are important in the removal of immune complexes from the circulation.	416
Summary		417

The destruction of antibody-coated pathogens via Fc receptors. 417

10-21	The Fc receptors of accessory cells are signaling receptors specific for immunoglobulins of different classes.	418
10-22	Fc receptors on phagocytes are activated by antibodies bound to the surface of pathogens and enable the phagocytes to ingest and destroy pathogens.	419
10-23	Fc receptors activate NK cells to destroy antibody-coated targets.	420
10-24	Mast cells and basophils bind IgE antibody via the high-affinity Fcε receptor.	421
10-25	IgE-mediated activation of accessory cells has an important role in resistance to parasite infection.	422
Summary		423
Summary to Chapter 10.		424
Questions.		425
General references.		426
Section references.		426

Chapter 11 Dynamics of Adaptive Immunity 429

The course of the immune response to infection. 430

11-1	The course of an infection can be divided into several distinct phases.	430
11-2	The nonspecific responses of innate immunity are necessary for an adaptive immune response to be initiated.	432
11-3	Cytokines made during infection can direct differentiation of CD4 T cells toward the T _H 17 subset.	434
11-4	T _H 1 and T _H 2 cells are induced by cytokines generated in response to different pathogens.	435
11-5	CD4 T-cell subsets can cross-regulate each other's differentiation.	437
11-6	Effector T cells are guided to sites of infection by chemokines and newly expressed adhesion molecules.	439
11-7	Differentiated effector T cells are not a static population but continue to respond to signals as they carry out their effector functions.	441
11-8	Primary CD8 T-cell responses to pathogens can occur in the absence of CD4 T-cell help.	442
11-9	Antibody responses develop in lymphoid tissues under the direction of T _{FH} cells.	444
11-10	Antibody responses are sustained in medullary cords and bone marrow.	445
11-11	The effector mechanisms used to clear an infection depend on the infectious agent.	445
11-12	Resolution of an infection is accompanied by the death of most of the effector cells and the generation of memory cells.	447
Summary		448

Immunological memory. 448

11-13	Immunological memory is long-lived after infection or vaccination.	449
11-14	Memory B-cell responses differ in several ways from those of naive B cells.	450
11-15	Repeated immunization leads to increasing affinity of antibody due to somatic hypermutation and selection by antigen in germinal centers.	451
11-16	Memory T cells are increased in frequency compared with naive T cells specific for the same antigen, and have distinct activation requirements and cell-surface proteins that distinguish them from effector T cells.	452

11-17	Memory T cells are heterogeneous and include central memory and effector memory subsets.	455
11-18	CD4 T-cell help is required for CD8 T-cell memory and involves CD40 and IL-2 signaling.	456
11-19	In immune individuals, secondary and subsequent responses are mainly attributable to memory lymphocytes.	458
	Summary.	459
	Summary to Chapter 11.	460
	Questions.	461
	Section references.	462

Chapter 12 The Mucosal Immune System 465

The organization of the mucosal system. 465

12-1	The mucosal immune system protects the internal surfaces of the body.	465
12-2	The mucosal immune system may be the original vertebrate immune system.	468
12-3	Cells of the mucosal immune system are located both in anatomically defined compartments and scattered throughout mucosal tissues.	468
12-4	The intestine has distinctive routes and mechanisms of antigen uptake.	472
12-5	The mucosal immune system contains large numbers of effector lymphocytes even in the absence of disease.	473
12-6	The circulation of lymphocytes within the mucosal immune system is controlled by tissue-specific adhesion molecules and chemokine receptors.	474
12-7	Priming of lymphocytes in one mucosal tissue can induce protective immunity at other mucosal surfaces.	475
12-8	Unique populations of dendritic cells control mucosal immune responses.	476
12-9	The intestinal lamina propria contains antigen-experienced T cells and populations of unusual innate-type lymphocytes.	478
12-10	The intestinal epithelium is a unique compartment of the immune system.	479
12-11	Secretory IgA is the class of antibody associated with the mucosal immune system.	482
12-12	IgA deficiency is common in humans but may be compensated for by secretory IgM.	485
	Summary.	486

The mucosal response to infection and regulation of mucosal immune responses. 486

12-13	Enteric pathogens cause a local inflammatory response and the development of protective immunity.	486
12-14	The outcome of infection by intestinal pathogens is determined by a complex interplay between the microorganism and the host immune response.	489
12-15	The mucosal immune system must maintain a balance between protective immunity and homeostasis to a large number of different foreign antigens.	491
12-16	The healthy intestine contains large quantities of bacteria but does not generate potentially harmful immune responses against them.	493
12-17	Full immune responses to commensal bacteria provoke intestinal disease.	497
12-18	Intestinal helminths provoke strong T_H2 -mediated immune responses.	498
12-19	Other eukaryotic parasites provoke protective immunity and pathology in the gut.	501
12-20	The mucosal immune system has to compromise between suppression and activation of an immune response.	501

Summary.	502
Summary to Chapter 12.	503
Questions.	504
General references.	504
Section references.	504

Part V THE IMMUNE SYSTEM IN HEALTH AND DISEASE

Chapter 13 Failures of Host Defense Mechanisms 509

Evasion and subversion of immune defenses. 509

13-1	Antigenic variation allows pathogens to escape from immunity.	510
13-2	Some viruses persist <i>in vivo</i> by ceasing to replicate until immunity wanes.	512
13-3	Some pathogens resist destruction by host defense mechanisms or exploit them for their own purposes.	514
13-4	Immunosuppression or inappropriate immune responses can contribute to persistent disease.	515
13-5	Immune responses can contribute directly to pathogenesis.	518
13-6	Regulatory T cells can affect the outcome of infectious disease.	518
	Summary.	519

Immunodeficiency diseases. 519

13-7	A history of repeated infections suggests a diagnosis of immunodeficiency.	520
13-8	Primary immunodeficiency diseases are caused by inherited gene defects.	520
13-9	Defects in T-cell development can result in severe combined immunodeficiencies.	522
13-10	SCID can also be due to defects in the purine salvage pathway.	523
13-11	Defects in antigen receptor gene rearrangement can result in SCID.	524
13-12	Defects in signaling from T-cell antigen receptors can cause severe immunodeficiency.	524
13-13	Genetic defects in thymic function that block T-cell development result in severe immunodeficiencies.	525
13-14	Defects in B-cell development result in deficiencies in antibody production that cause an inability to clear extracellular bacteria.	527
13-15	Immune deficiencies can be caused by defects in B-cell or T-cell activation and function.	528
13-16	Defects in complement components and complement-regulatory proteins cause defective humoral immune function and tissue damage.	532
13-17	Defects in phagocytic cells permit widespread bacterial infections.	533
13-18	Mutation in the molecular regulators of inflammation can cause uncontrolled inflammatory responses that result in 'autoinflammatory disease.'	536
13-19	The normal pathways for host defense against intracellular bacteria are pinpointed by genetic deficiencies of IFN- γ and IL-12 and their receptors.	538
13-20	X-linked lymphoproliferative syndrome is associated with fatal infection by Epstein-Barr virus and with the development of lymphomas.	539

13-21	Genetic abnormalities in the secretory cytotoxic pathway of lymphocytes cause uncontrolled lymphoproliferation and inflammatory responses to viral infections.	539
13-22	Hematopoietic stem cell transplantation or gene therapy can be useful to correct genetic defects.	541
13-23	Secondary immunodeficiencies are major predisposing causes of infection and death.	542
Summary.		543

Acquired immune deficiency syndrome. 543

13-24	Most individuals infected with HIV progress over time to AIDS.	545
13-25	HIV is a retrovirus that infects CD4 T cells, dendritic cells, and macrophages.	547
13-26	Genetic variation in the host can alter the rate of progression of disease.	549
13-27	A genetic deficiency of the co-receptor CCR5 confers resistance to HIV infection <i>in vivo</i> .	549
13-28	HIV RNA is transcribed by viral reverse transcriptase into DNA that integrates into the host-cell genome.	551
13-29	Replication of HIV occurs only in activated T cells.	551
13-30	Lymphoid tissue is the major reservoir of HIV infection.	554
13-31	An immune response controls but does not eliminate HIV.	554
13-32	The destruction of immune function as a result of HIV infection leads to increased susceptibility to opportunistic infection and eventually to death.	556
13-33	Drugs that block HIV replication lead to a rapid decrease in titer of infectious virus and an increase in CD4 T cells.	557
13-34	HIV accumulates many mutations in the course of infection, and drug treatment is soon followed by the outgrowth of drug-resistant variants.	559
13-35	Vaccination against HIV is an attractive solution but poses many difficulties.	560
13-36	Prevention and education are one way in which the spread of HIV and AIDS can be controlled.	561
Summary.		562
Summary to Chapter 13.		562
Questions.		563
General references.		564
Section references.		564

Chapter 14 Allergy and Allergic Diseases 571

IgE and IgE-mediated allergic diseases. 573

14-1	Sensitization involves class switching to IgE production on first contact with an allergen.	573
14-2	Allergens are usually delivered transmucosally at low dose, a route that favors IgE production.	575
14-3	Genetic factors contribute to the development of IgE-mediated allergic disease.	577
14-4	Environmental factors may interact with genetic susceptibility to cause allergic disease.	579
14-5	Regulatory T cells can control allergic responses.	581
Summary.		582

Effector mechanisms in IgE-mediated allergic reactions. 582

14-6	Most IgE is cell-bound and engages effector mechanisms of the immune system by different pathways from those of other antibody isotypes.	583
14-7	Mast cells reside in tissues and orchestrate allergic reactions.	583

14-8	Eosinophils and basophils cause inflammation and tissue damage in allergic reactions.	585
14-9	IgE-mediated allergic reactions have a rapid onset but can also lead to chronic responses.	587
14-10	Allergen introduced into the bloodstream can cause anaphylaxis.	589
14-11	Allergen inhalation is associated with the development of rhinitis and asthma.	591
14-12	A genetically determined defect in the skin's barrier function increases the risk of atopic eczema.	592
14-13	Allergy to particular foods causes systemic reactions as well as symptoms limited to the gut.	594
14-14	IgE-mediated allergic disease can be treated by inhibiting the effector pathways that lead to symptoms or by desensitization techniques that aim at restoring tolerance to the allergen.	595
Summary.		597

Non-IgE-mediated allergic diseases. 598

14-15	Innocuous antigens can cause type II hypersensitivity reactions in susceptible individuals by binding to the surfaces of circulating blood cells.	598
14-16	Systemic disease caused by immune-complex formation can follow the administration of large quantities of poorly catabolized antigens.	598
14-17	Hypersensitivity reactions can be mediated by T_H1 cells and CD8 cytotoxic T cells.	600
14-18	Celiac disease has features of both an allergic response and autoimmunity.	603
Summary.		605
Summary to Chapter 14.		606
Questions.		606
General references.		607
Section references.		607

Chapter 15 Autoimmunity and Transplantation 611

The making and breaking of self-tolerance. 611

15-1	A critical function of the immune system is to discriminate self from nonself.	612
15-2	Multiple tolerance mechanisms normally prevent autoimmunity.	613
15-3	Central deletion or inactivation of newly formed lymphocytes is the first checkpoint of self-tolerance.	614
15-4	Lymphocytes that bind self antigens with relatively low affinity usually ignore them but in some circumstances become activated.	616
15-5	Antigens in immunologically privileged sites do not induce immune attack but can serve as targets.	617
15-6	Autoreactive T cells that express particular cytokines may be nonpathogenic or may suppress pathogenic lymphocytes.	619
15-7	Autoimmune responses can be controlled at various stages by regulatory T cells.	619
Summary.		621

Autoimmune diseases and pathogenic mechanisms. 622

15-8	Specific adaptive immune responses to self antigens can cause autoimmune disease.	622
15-9	Autoimmune diseases can be classified into clusters that are typically either organ-specific or systemic.	623
15-10	Multiple components of the immune system are typically recruited in autoimmune disease.	624

15-11	Chronic autoimmune disease develops through positive feedback from inflammation, inability to clear the self antigen, and a broadening of the autoimmune response.	625	15-38	The fetus is an allograft that is tolerated repeatedly.	661
15-12	Both antibody and effector T cells can cause tissue damage in autoimmune disease.	629		Summary.	663
15-13	Autoantibodies against blood cells promote their destruction.	631		Summary to Chapter 15.	663
15-14	The fixation of sublytic doses of complement to cells in tissues stimulates a powerful inflammatory response.	632		Questions.	664
15-15	Autoantibodies against receptors cause disease by stimulating or blocking receptor function.	632		Section references.	665
15-16	Autoantibodies against extracellular antigens cause inflammatory injury by mechanisms akin to type II and type III hypersensitivity reactions.	632			
15-17	T cells specific for self antigens can cause direct tissue injury and sustain autoantibody responses.	635			
	Summary.	638			
	The genetic and environmental basis of autoimmunity.	639		Chapter 16 Manipulation of the Immune Response	669
15-18	Autoimmune diseases have a strong genetic component.	639		Treatment of unwanted immune responses.	669
15-19	Several approaches have given us insight into the genetic basis of autoimmunity.	640	16-1	Corticosteroids are powerful anti-inflammatory drugs that alter the transcription of many genes.	670
15-20	Many genes that predispose to autoimmunity fall into categories that affect one or more of the mechanisms of tolerance.	642	16-2	Cytotoxic drugs cause immunosuppression by killing dividing cells and have serious side-effects.	671
15-21	A defect in a single gene can cause autoimmune disease.	643	16-3	Cyclosporin A, tacrolimus (FK506), and rapamycin (sirolimus) are powerful immunosuppressive agents that interfere with T-cell signaling.	671
15-22	MHC genes have an important role in controlling susceptibility to autoimmune disease.	644	16-4	Antibodies against cell-surface molecules can be used to eliminate lymphocyte subsets or to inhibit lymphocyte function.	674
15-23	Genetic variants that impair innate immune responses can predispose to T cell-mediated chronic inflammatory disease.	647	16-5	Antibodies can be engineered to reduce their immunogenicity in humans.	674
15-24	External events can initiate autoimmunity.	648	16-6	Monoclonal antibodies can be used to prevent allograft rejection.	675
15-25	Infection can lead to autoimmune disease by providing an environment that promotes lymphocyte activation.	649	16-7	Depletion of autoreactive lymphocytes can treat autoimmune disease.	677
15-26	Cross-reactivity between foreign molecules on pathogens and self molecules can lead to anti-self responses and autoimmune disease.	649	16-8	Biologic agents that block TNF- α or IL-1 can alleviate autoimmune diseases.	678
15-27	Drugs and toxins can cause autoimmune syndromes.	651	16-9	Biologic agents can block cell migration to sites of inflammation and reduce immune responses.	679
15-28	Random events may be required for the initiation of autoimmunity.	651	16-10	Blockade of co-stimulatory pathways that activate lymphocytes can be used to treat autoimmune disease.	680
	Summary.	651	16-11	Some commonly used drugs have immunomodulatory properties.	681
	Responses to alloantigens and transplant rejection.	652	16-12	Controlled administration of antigen can be used to manipulate the nature of an antigen-specific response.	681
15-29	Graft rejection is an immunological response mediated primarily by T cells.	652		Summary.	682
15-30	Transplant rejection is caused primarily by the strong immune response to nonself MHC molecules.	653		Using the immune response to attack tumors.	682
15-31	In MHC-identical grafts, rejection is caused by peptides from other alloantigens bound to graft MHC molecules.	654	16-13	The development of transplantable tumors in mice led to the discovery of protective immune responses to tumors.	684
15-32	There are two ways of presenting alloantigens on the transplanted donor organ to the recipient's T lymphocytes.	655	16-14	Tumors are 'edited' by the immune system as they evolve and can escape rejection in many ways.	684
15-33	Antibodies that react with endothelium cause hyperacute graft rejection.	657	16-15	Tumor-specific antigens can be recognized by T cells and form the basis of immunotherapies.	687
15-34	Late failure of transplanted organs is caused by chronic injury to the graft.	658	16-16	Monoclonal antibodies against tumor antigens, alone or linked to toxins, can control tumor growth.	691
15-35	A variety of organs are transplanted routinely in clinical medicine.	659	16-17	Enhancing the immune response to tumors by vaccination holds promise for cancer prevention and therapy.	693
15-36	The converse of graft rejection is graft-versus-host disease.	659	16-18	Checkpoint blockade can augment immune responses to existing tumors.	694
15-37	Regulatory T cells are involved in alloreactive immune responses.	661		Summary.	696
				Fighting infectious diseases with vaccination.	697
			16-19	Vaccines can be based on attenuated pathogens or material from killed organisms.	698
			16-20	Most effective vaccines generate antibodies that prevent the damage caused by toxins or that neutralize the pathogen and stop infection.	699
			16-21	Effective vaccines must induce long-lasting protection while being safe and inexpensive.	700

16-22	Live-attenuated viral vaccines are usually more potent than 'killed' vaccines and can be made safer by the use of recombinant DNA technology.	700	Isolation of lymphocytes.	739	
16-23	Live-attenuated vaccines can be developed by selecting nonpathogenic or disabled bacteria or by creating genetically attenuated parasites (GAPs).	702	A-20	Isolation of peripheral blood lymphocytes by Ficoll-Hypaque™ gradient.	739
16-24	The route of vaccination is an important determinant of success.	702	A-21	Isolation of lymphocytes from tissues other than blood.	740
16-25	<i>Bordetella pertussis</i> vaccination illustrates the importance of the perceived safety of a vaccine.	704	A-22	Flow cytometry and FACS analysis.	740
16-26	Conjugate vaccines have been developed as a result of understanding how T and B cells collaborate in an immune response.	705	A-23	Lymphocyte isolation using antibody-coated magnetic beads.	742
16-27	Peptide-based vaccines can elicit protective immunity, but they require adjuvants and must be targeted to the appropriate cells and cell compartment to be effective.	705	A-24	Isolation of homogeneous T-cell lines.	742
16-28	Adjuvants are important for enhancing the immunogenicity of vaccines, but few are approved for use in humans.	707	Characterization of lymphocyte specificity, frequency, and function.	743	
16-29	Protective immunity can be induced by DNA-based vaccination.	708	A-25	Limiting-dilution culture.	744
16-30	The effectiveness of a vaccine can be enhanced by targeting it to sites of antigen presentation.	708	A-26	ELISPOT assays.	745
16-31	An important question is whether vaccination can be used therapeutically to control existing chronic infections.	709	A-27	Identification of functional subsets of T cells by staining for cytokines.	746
Summary.		710	A-28	Identification of T-cell receptor specificity using peptide:MHC tetramers.	746
Summary to Chapter 16.		711	A-29	Assessing the diversity of the T-cell repertoire by 'spectratyping.'	748
Questions.		711	A-30	Biosensor assays for measuring the rates of association and disassociation of antigen receptors for their ligands.	749
General references.		712	A-31	Stimulation of lymphocyte proliferation by treatment with polyclonal mitogens or specific antigen.	750
Section references.		712	A-32	Measurements of apoptosis by the TUNEL assay.	751
			A-33	Assays for cytotoxic T cells.	751
			A-34	Assays for CD4 T cells.	751
Appendix I The Immunologist's Toolbox		717	Detection of immunity <i>in vivo</i>.	753	
Immunization.		717	A-35	Assessment of protective immunity.	753
A-1	Haptens.	718	A-36	Transfer of protective immunity.	753
A-2	Routes of immunization.	720	A-37	The tuberculin test.	754
A-3	Effects of antigen dose.	720	A-38	Testing for allergic responses.	754
A-4	Adjuvants.	720	A-39	Assessment of immune responses and immunological competence in humans.	754
The detection, measurement, and characterization of antibodies and their use as research and diagnostic tools.		723	A-40	The Arthus reaction.	756
A-5	Affinity chromatography.	723	A-41	Adoptive transfer of lymphocytes.	756
A-6	Radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and competitive inhibition assay.	723	A-42	Hematopoietic stem-cell transfers.	757
A-7	Hemagglutination and blood typing.	724	A-43	<i>In vivo</i> depletion of T cells.	757
A-8	Precipitin reaction.	725	A-44	<i>In vivo</i> depletion of B cells.	757
A-9	Equilibrium dialysis: measurement of antibody affinity and avidity.	727	A-45	Transgenic mice.	758
A-10	Anti-immunoglobulin antibodies.	727	A-46	Gene knockout by targeted disruption.	759
A-11	Coombs tests and the detection of Rhesus incompatibility.	729	Appendix II CD Antigens	763	
A-12	Monoclonal antibodies.	730	Appendix III Cytokines and Their Receptors	779	
A-13	Phage display libraries for antibody V-region production.	731	Appendix IV Chemokines and Their Receptors	782	
A-14	Microscopy and imaging.	732	Biographies	784	
A-15	Immunoelectron microscopy.	734	Photograph Acknowledgments	785	
A-16	Immunohistochemistry.	735	Glossary	786	
A-17	Immunoprecipitation and co-immunoprecipitation.	735	Index	823	
A-18	Immunoblotting (Western blotting).	737			
A-19	Use of antibodies in the isolation and identification of genes and their products.	737			